Aim: Small molecule activators of glucokinase (GKAs) have been explored extensively as potential anti-hyperglycaemic drugs for type 2 diabetes (T2D). Several GKAs were remarkably effective in lowering blood glucose during early therapy but then lost their glycaemic efficacy chronically during clinical trials.
debated. [1] [2] [3] Its mechanism involves inhibition of mitochondrial complex I and other effects that are either dependent on activation of AMPK or independent of this kinase.
2-5
In recent years, major effort has been focused on candidate drugs targeting glucokinase, which is the first enzyme involved in glucose metabolism in the liver and insulin secretory cells. 6 In the liver, glucokinase is regulated by adaptive binding to an inhibitor protein,
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GKRP, which sequesters glucokinase in an inactive state in the nucleus at basal blood glucose. 7 GKRP enables adaptive translocation of glucokinase to the cytoplasm after a meal, in response to fructose or raised blood glucose. Small molecule glucokinase activators (GKAs) have been identified; these bind to an allosteric site causing enzyme activation in hepatocytes, improved glucose tolerance and lowering of blood glucose in animal models and in human diabetes. [6] [7] [8] [9] However, despite very good initial efficacy in controlling blood glucose in T2D, this efficacy declined rather rapidly during clinical trials. [10] [11] [12] Whether this loss of efficacy is explained by a rise in blood triglycerides is unsettled. [10] [11] [12] [13] High glucose concentration represses the glucokinase gene (Gck) in hepatocytes, concomitantly with induction of glucose 6-phosphatase (G6pc) which catalyses the final reaction in hepatic glucose production. 14, 15 This effect of glucose is often described as glucotoxicity because induction in G6pc and, thereby, hepatic glucose production by hyperglycaemia is counter-intuitive. However, repression of Gck and induction of G6pc by high glucose can be rationalized as a mechanism for preserving intracellular metabolite homeostasis at the expense of worsening hyperglycaemia. 16 In this study we tested the hypothesis that treatment of hepatocytes with a GKA represses the Gck gene by a mechanism linked to raised cell metabolites. We also tested whether metformin, which has effects on glucokinase translocation opposite to those of GKAs, [17] [18] [19] also has effects on cell metabolites and gene regulation at high glucose that are converse to those of the GKA.
| MATERIALS AND METHODS

| Materials
The GKA Ro28-1675 20 was from Axon MedChem BV (Groningen, The Netherlands). STK017597, an inhibitor of mGPD, 21 was from Vitas-M Laboratory (Kowloon, Hong Kong); S4048, a G6P transport inhibitor, 22 was a gift from Sanofi Aventis.
| Hepatocyte isolation and culture
Hepatocytes were isolated from male Wistar rats (body weight, 200-300 g) from Envigo (Bicester, UK). 17 Procedures conformed to Home
Office Regulations and were approved by the University Ethics Committee. The hepatocytes were suspended in Minimum Essential
Medium with 5% (v/v) calf serum and were seeded on gelatin-coated plates. 17 After cell attachment, the medium was replaced by serumfree medium containing 5 mM glucose, 10 nM dexamethasone, 1 nM insulin and experiments were started after c. 20 hours of culture.
Unless otherwise stated, the medium contained 5 mM glucose.
| Hepatocyte incubations
Parallel incubations were performed for RNA extraction and metabolite determination. Glucose phosphorylation was determined with [2-3 H]glucose (1 μCi/mL). 17 For determination of metformin uptake, hepatocytes were incubated with 14 C-metformin (0.5 μCi/mL) and incubations were terminated by 2 rapid washes with 300 mM sucrose. Incubations for metabolite determination were terminated 1 or 2 hours after substrate addition. Time courses showed maximum G6P elevation at 1 to 2 hours with 25 mM glucose. 
| Mouse study
| Metabolite determination
The medium was aspirated and plates were snap-frozen in liquid nitrogen and stored at −80 C. 14, 15 For hexose 6-P and adenine nucleotide determination, cells were extracted in 2.5% sulphosalicylic acid for deproteinization (10 000 g, 10 minutes) and metabolites were assayed on neutralized deproteinized extracts. Glucose 6-P (G6P) and 2-deoxyglucose 6-P (DG6P) were determined fluorometrically, 15 and adenine nucleotides were determined by a luciferase-coupled luminometric method. 14 For fructose 2,6-P 2 cells were extracted in 0.15 M NaOH. 15 Except for fructose 2,6-P 2 (pmol/mg), other metabolites are expressed as nmol/mg protein.
| Immunostaining and immunoactivity
Hepatocytes were fixed and immunostained for glucokinase (Santa Cruz, sc7908). 17 For each condition, 10 fields (≥30 cells/field) were imaged for determination of the nuclear/cytoplasmic (N/C) ratio.
Results are from 3 hepatocyte preparations. Immunoactivity to glucokinase and actin was as described previously 17 and to phospho-acetyl-CoA carboxylase (ser79-P) with an antibody from New England Biolabs (#3661).
| mRNA analysis
RNA was extracted using TRIzol (Invitrogen) and cDNA was synthesized from 1 μg of RNA with MMLV (Promega). Real-time RT-PCR was performed in a total volume of 10 μL containing 50 ng of reverse transcribed RNA and 5 ng of forward and reverse primers, using a Sybr-Green protocol (Promega) in a Roche Capillary Light Cycler. 14 Primers were as described previously. 14, 23 Relative mRNA levels (vs control) were calculated by the delta cycle threshold method.
| Chromatin immunoprecipitation (ChIP)
Hepatocytes were cultured in 150 cm 2 dishes and incubations were terminated with formaldehyde (1%v/v, 10 minutes) followed by glycine (0.125 M, 5 minutes). 23 Binding of Mlx, ChREBP or IgG to G6pc
and Pklr promoters was as described previously. 23 After pre-clearing, supernatants were incubated overnight (4 C) with 6 μg IgG against ChREBP (Novus Biologicals, NB400-135), Mlx or control (sc-14705;
sc-2027). DNA was extracted with phenol/chloroform, amplified by real-time PCR and is expressed as % input.
| Statistical analysis
Data are given as means AE S.E.M. for the number of hepatocyte preparations indicated. Statistical analysis was by Student's t-test (paired or unpaired) or 2-way ANOVA with Bonferroni correction for ChIP.
Correlations were made by linear regression.
3 | RESULTS
| A GKA causes a left-shift in glucose-regulated gene expression
In hepatocytes challenged with 25 mM glucose several genes are either induced or repressed 24 by a mechanism linked to raised cell metabolite levels rather than metabolic flux. 14, 15 We determined the effects of a GKA 20 on glucose phosphorylation flux and hepatocyte G6P. The GKA increased phosphorylation flux and cell G6P at all glucose concentrations tested without changing ATP ( Figure 1A -C). At 15 mM glucose with GKA, cell G6P, but not flux, was higher (P < .05)
than that at 25 mM glucose alone ( Figure 1B ). Therefore, we used 15 mM glucose ( Figure 1D -H) to compare the GKA with 2 mM fructose (2F) and with 25 mM glucose (25G), which, like the GKA, promote glucokinase translocation. 7, 17 High glucose (25 mM) repressed Gck ( Figure 1D ) and induced Pklr and G6pc ( 
| Repression of Gck by fructose correlates with G6P
Chronic feeding of animal models with fructose or sucrose has been found to either increase or decrease glucokinase protein or activity. [25] [26] [27] In mice fed a high-energy diet with fructose, we found lower liver glucokinase protein (Figure 2A ). Converse effects of dietary fructose in different studies [25] [26] [27] may be explained by the opposite effects on hyperinsulinaemia, 26 compared with the effects of fructose on liver Gck expression. Alternatively, the directional effect of fructose on Gck expression may be dose-dependent because low fructose (<2 mM) promotes glucokinase translocation, similar to the GKA, but high fructose (>2 mM) depletes cell ATP by depleting inorganic phosphate 28 ( Figure 2B ). We tested the effect of 2 to 10 mM fructose at basal or high glucose. Compared with 25 mM glucose, fructose (10 mM) caused similar elevation of G6P ( Figure 2C ), lower elevation in fructose 2,6-P 2 ( Figure 2D ), similar repression of Gck ( Figure 2E ) and lower induction of G6pc ( Figure 2F ). Gck correlated negatively with G6P (r = 0.9, P < .003; Figure 2G ) and G6pc correlated positively (r = 0.88, P < .004; Figure 2H ) with fructose 2,6-P 2 but not with G6P (r = 0.36, P = .39). Five other ChREBP target genes responded to fructose similarly to the response of G6pc (results not shown).
| Repression of Gck by 2-deoxyglucose (DG) implicates hexose 6-P
To distinguish between a role for G6P or hexose 6-P (H6P) as distinct from fructose 2,6-P 2 in gene regulation, we used 2-deoxyglucose (DG), which is phosphorylated by glucokinase to DG6P, but not further metabolized by glycolysis ( Figure 3A) . We used S4048 to further raise H6P by inhibiting transport and hydrolysis of DG6P. 15,29 DG (5-10 mM) raised H6P levels ( Figure 3B ), inhibited glucose metabolism ( Figure 3C ) and lowered fructose 2,6-P 2 ( Figure 3D ). Unlike high fructose, DG did not lower ATP ( Figure 3E ) or increase uric acid production (not shown), which is a marker of transient ATP depletion. 28 DG
repressed Gck ( Figure 3F ) but did not induce G6pc or other ChREBP targets such as G6pd and Me1 ( Figure 3G ,H) and Gck mRNA correlated negatively (r − 0.89, P < .003) with H6P ( Figure 3I ).
| Metformin antagonizes gene regulation by high glucose
Previous studies reported that GKAs stimulate, 17 and high metformin concentrations (>1 mM) inhibit, 18, 19 glucokinase translocation. We confirmed that the GKA (Ro 28-1675) promotes translocation of glucokinase and that metformin (≥1 mM) inhibits translocation at high glucose ( Figure S1 ). We next tested whether these metformin concentrations have effects opposite to those of the GKA on gene regulation at high glucose in either the presence of insulin ( Figure 4A-D) or its absence ( Figure 4E,F) . In the presence of insulin, metformin induced Gck at 5 and 25 mM glucose ( Figure 4A ) and had no effect on Pklr, G6pc and Txnip at 5 mM glucose, but counteracted the induction by 25 mM glucose ( Figure 4B-D) . In the absence of insulin, metformin likewise counteracted induction of G6pc and Txnip by high glucose but had no effect at 5 mM glucose ( Figure 4E,F) . This indicates counter-effects of metformin on gene induction by high glucose that are independent of insulin signalling. We tested the effects of compound C (CC), an inhibitor of AMPK and various other protein kinases 30 that blocks the metformin induction of FGF21. 31 This inhibitor partly attenuated (≤25%) but did not abolish the metformin effect at high glucose ( Figure 5G,H) , implicating a mechanism different from that of FGF21 induction. 31 Fructose 2,6-P 2 , which is involved in ChREBP-translocation by high glucose, 15, 23 was lowered by metformin at 5 and 25 mM glucose ( Figure 5I ) and recruitment of Mlx and
ChREBP to the Pklr and G6pc promoters by high glucose was also inhibited by metformin ( Figure 5J ,K).
| Low metformin lowers G6P at high glucose
When assessing whether the exposure to metformin in cellular studies corresponds to therapeutic doses in man, 32 both incubation time and cellular metformin content are relevant. Metformin is cationic at physiological pH and is transported across the cell membrane by organic cation transporters 2 and distributes ("accumulates") in cells 33 in accordance with transmembrane potential. 2, 34 The time lag in metformin efficacy in cellular studies is due in part to slow equilibration. 34 In man, blood metformin levels after an oral dose peak at 3 hours (8-23 μM for a 0.5-1.5 g metformin dose) and then decline, with a mean elimination half-life of 5 hours and a urinary excretion t½ of 20 hours. 32 In mice given an equivalent oral metformin load (50 mg/kg), blood metformin levels peak at 0.5 to 1 hour (c. 28 μM)
and decline more rapidly than in man. 32, 33 The peak hepatic content of metformin in mice is higher than the coincident blood peak in the periphery and portal vein, as expected 2, 34 and was 182 to 282 nmol/g liver, which approximates to 1 to 2 nmol/mg protein (based on 10 8 hepatocytes per g and 1.7 mg protein per million hepatocytes). 33 We used This indicates that metformin loads ≥1 to 2 nmol/mg have converse effects on gene regulation from the GKA (Figure 1 ).
| DISCUSSION
The low liver glucokinase activity and Gck mRNA in poorly controlled T2D 36,37 is generally attributed to impaired Gck induction by insulin. 37 However, animal studies using either hyperglycaemic clamps 38 FIGURE 2 Repression of Gck by fructose. A, Glucokinase immunoactivity in livers of mice fed a high-energy fructose-containing diet (HEFD). Means AE SEM, n = 11, P < .02 relative to control. B, Fructose is metabolized to fructose 1-P (F1P), which activates glucokinase by dissociating it from GKRP. At high fructose (>2 mM) accumulation of F1P causes depletion of inorganic phosphate (Pi) and ATP by limiting oxidative phosphorylation (OP). C-F, Incubations were with 10 nM insulin and 5 or 25 mM glucose (5G/25G) and 2 to 10 mM fructose (F) for either 2 hours (C,D) for G6P and fructose 2,6-P 2 or 4 hours (E,F) for mRNA analysis. Means AE SEM, n = 3 to 8. *P < .05 effect of fructose; #P < .05 relative to 25G. G,H, Correlation of mRNA versus metabolite or chronic treatment of hyperglycaemia with inhibitors of renal glucose reabsorption 39,40 support a mechanism for repression of glucokinase by hyperglycaemia. 7 Key questions are whether this repression is the result of glucose per se 40 or of raised intracellular metabolites derived from glucose. 7 The latter would implicate potential links between antihyperglycaemic drugs that affect glucose metabolites and liver Gck expression. We show in this study that a GKA mimics the repression of Gck by high glucose, whereas metformin has the opposite effect.
We identified 3 conditions mimicking Gck repression by 25 mM glucose in hepatocytes: (1) the GKA at basal or moderate glucose (5-15 mM); (2) fructose, 2 to 10 mM; (3) 2-deoxyglucose. In all conditions Gck mRNA correlated inversely with hexose 6-P levels (Figures 1-3) . The 2-deoxyglucose experiments implicate the raised hexose 6-P in the Gck repression, but do not exclude involvement of other metabolites. We showed previously that in hepatocytes incubated with high glucose, selective lowering of fructose 2,6-P 2, (without lowering G6P) by overexpression of a kinase-deficient bisphosphatase variant of PFKFB2 raised Gck expression. 15 This implicates a potential dual role for hexose 6-P (present study) and fructose 2,6-P 2 15 in Gck repression. The rapid (within 4 hours)
"metabolite repression" of liver Gck in hepatocytes concurs with acute repression of liver Gck mRNA in rats treated with S4048, which raises hepatic G6P but not blood glucose, 29 or with a liver-selective GKA before glucose tolerance testing. 41 A key question is how one reconciles this mechanism with the chronic effects of GKAs over a time scale of months [10] [11] [12] or with a high-fructose diet. [25] [26] [27] Repression of glucokinase protein or activity by fructose-containing diets in some, but not other, studies [25] [26] [27] could be explained by the opposing effects of Gck repression caused by fructose (Figure 2 ) vs induction by secondary hyperinsulinaemia. 26 The half-life of glucokinase protein is 4.6 days, that is, 2 orders of magnitude longer than that of mRNA.
14 If metabolite repression of liver GCK were the only adaptive mechanism to the GKA, then loss of liver glucokinase protein would be expected within 4 to 7 days, as occurs during fasting. 7 However, loss of glycaemic efficacy of GKAs that target both liver and pancreatic islets occurred in man after 4 weeks, 10, 11 and in some preclinical studies this manifested earlier. 41, 42 For GKAs that target both liver and pancreatic islets, the latter effect leads to raised insulin release into the portal vein, which induces the liver GCK gene. 7 This could explain why the glycaemic response to GKAs improves progressively for the first 4 weeks before it declines. 10, 11 The first phase may represent insulin induction of liver GCK and the second metabolite repression. The possibility that tachyphylaxis 10, 11 is also the result of loss of GKA efficacy in pancreatic islets cannot be excluded. However, liver-selective GKAs are effective in lowering blood glucose, 43 and more so initially than chronically. 41 Furthermore, in a mouse model of an activating Gck mutation, liver glucokinase protein is markedly decreased despite preserved glucose-induced insulin secretion, and in the absence of raised lipids. 44 This suggests that downregulation of liver glucokinase protein can occur in the absence of steatosis with a Gck activating mutation. Absence of steatosis was also noted in patients with GCK activating mutations. 45 Cumulatively, the present data suggest that metabolite repression of the liver GCK gene is a plausible component of tachyphylaxis to GKAs. 10, 11 However, in the clinical setting for GKAs that also target the pancreas, tachyphylaxis in islets might be an additional mechanism.
Metformin was exploited as an anti-hyperglycaemic agent for T2D long before its mechanism of action was explored. Despite clear evidence for AMPK activation by metformin, 4 also at low concentrations, 46 there remain cogent arguments for AMPKindependent mechanisms. 3, 5 Here we focused on the effects of metformin on gene regulation at high glucose, because this is the defining feature of T2D and because previous work with high metformin (≥2 mM) reported inhibition of glucokinase translocation, 18, 19 which is an opposite response to GKAs. 17 We report that low metformin concentrations (≥0.1 mM) in incubation times of 2 to 4 hours, that lead to cell metformin loads of 1 to 2 nmol/mg, attenuate G6P levels in conditions of elevated glucose and have effects on glucoseresponsive genes opposite to those of the GKA. Lowering of liver G6P in rats at 4 hours after treatment with metformin has been observed previously. 34 In the present study, the lowering of G6P by metformin was not blocked by an inhibitor of mGPD 21 and it was not mimicked by A769662, an AMPK activator. 35 However, in the absence of studies on AMPK-deficient cells, we cannot firmly exclude a role for AMPK activation.
A key finding from this study is that metformin lowers G6P in hepatocytes in conditions of elevated glucose and at a cellular load of metformin that occurs during the absorptive phase in mouse liver after an oral therapeutic dose of metformin. 33 One limitation of our study is that, after a 2-hour incubation of hepatocytes with low extracellular metformin concentrations, the intracellular concentrations are quasi static and, therefore, not the same as the dynamic changes that occur in liver after an oral therapeutic dose of metformin 33 when blood metformin levels rise rapidly and decline with a Means AE SEM, n = 3 to 8, *P < .05 effect of metformin, # P < .05 effect of compound C. I, Fructose 2,6-P 2 (pmol/mg protein). Means AE SEM, n = 3, *P < .05 effect of metformin. J-K, Chromatin immunoprecipitation for binding of Mlx and ChREBP to the Pklr and G6pc promoters after 4 hour incubation expressed as % input. Means AE SEM, n = 3, *P < .05 effect of metformin half-life of 2 to 6 hours. 32, 33 Given the differences in dynamic changes between cellular models ( Figure 5 ) and the liver in vivo, 33 it is uncertain whether therapeutic doses of metformin will attenuate hepatic G6P in man, as occurs in animal models, 34 and whether such changes, if they occur in man, would be confined to the absorptive phase of metformin when blood levels are highest. 32, 47 
